Similar companies
Income Statement (USD)
| Q1 '25 | QoQ | |
|---|---|---|
| Revenue | 745M | 13.1% |
| Gross Profit | 607M | 15.4% |
| Cost of Revenue | 138M | 4% |
| Operating expense | 1.05B | 186.8% |
| Net Income | -448M | 381.4% |
Balance Sheet (USD)
| Q1 '25 | QoQ |
|---|
Cash Flow (USD)
| Q1 '25 | QoQ |
|---|
EPS
Financial Highlights for Sarepta Therapeutics in Q1 '25
Sarepta Therapeutics reported a revenue of 745M, which is a 13.1% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 607M, marking a 15.4% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 138M, a 4% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 1.05B, showing a 186.8% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -448M, showing a -381.4% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
Sarepta Therapeutics faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. Higher operating expenses might indicate increased investments or potential inefficiencies. A decline in EBITDA signals potential operational challenges or increased costs.
